MSD
@MSDInvents
Followers
24K
Following
540
Media
2K
Statuses
2K
We aspire to be the premier research-intensive biopharmaceutical company.
Global
Joined October 2016
Our Q1 2025 #earnings results are live. Check out our full financial summary and key highlights:
0
0
3
Today, we announced an exclusive license to develop, manufacture and commercialize an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Learn more:
1
0
5
Our Q4 and full-year 2024 #earnings results are live. Check out our full financial summary and key highlights:
0
0
2
Today we announced an exclusive global license to develop, manufacture and commercialize an investigational preclinical oral small molecule GLP-1 receptor agonist from Hansoh Pharma. Learn more:
0
1
4
Today we announced an exclusive global license to develop, manufacture and commercialize a novel investigational bispecific antibody from LaNova Medicines Ltd. Learn more:
0
2
4
Our Q3 2024 #earnings results are live. Check out our full financial summary and key highlights:
0
2
1
Today, we announced an agreement to acquire .Modifi Bio and the company’s preclinical compounds designed to exploit DNA repair defects in difficult to treat forms of #cancer.
0
1
4
Today, we shared positive results from our late-stage clinical program in respiratory syncytial virus (#RSV) disease. Learn more here:
0
0
1
Today, we announced the completion of our acquisition of a novel investigational bispecific antibody from Curon Biopharmaceutical offering applications in B-cell malignancies and autoimmune diseases and further broadening our pipeline. Read more:
0
0
7
Today, we announced the acquisition of a novel investigational bispecific antibody from Curon Biopharma. Learn how this further expands and diversifies our growing pipeline, with potential applications in B-cell malignancies and autoimmune diseases:
0
0
5
Today, we announced that we’ve expanded our global development and commercialization agreement with Daiichi Sankyo. Read more here:
0
0
4